NSE · ANTHEM
Anthem Biosciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹572 Cr with net profit ₹221 Cr — a 38.61% net margin, versus 26.58% the period before.
Shareholding
As of 2026-09-30
- Promoter71.4%
- Public12.7%
- FII3.79%
- DII12.1%
1,76,209 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.69× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #12 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Anthem Biosciences Ltd.(this company) | ₹51,589 Cr | 81.75 | 15.7 | 18.71% | 30% |
AI analysis
AI-generated · google/gemini-2.5-flashAnthem Biosciences Ltd. is listed with a market capitalization of Rs 43760 Cr. The company reported revenue of Rs 1930.29 Cr and an EPS of Rs 8.07. Its book value is Rs 43.1.
Positives
- +The company has a low debt-to-equity ratio of 0.08.
- +Return on Equity (ROE) is 20.8%.
- +Return on Capital Employed (ROCE) is 26.7029%.
- +Promoter holding of 71.4165% as of June 30, 2026 is high.
- +There are no promoter shares pledged as of June 30, 2026.
Negatives
- −The Promoter holding decreased from 74.6758% on March 31, 2026 to 71.4165% on June 30, 2026.
- −Consolidated revenue growth data is not available.
Financial Performance
In the annual period ending March 2026, Anthem Biosciences Ltd. reported revenue of Rs 2280.116 Cr and a net profit of Rs 591.792 Cr, with an EPS of Rs 10.43. For the quarter ending June 2026, the company recorded revenue of Rs 418.22 Cr and a net profit of Rs 119.94 Cr.
Profitability & Returns
The company's Return on Equity (ROE) stands at 20.8%, and its Return on Capital Employed (ROCE) is 26.7029%. The Earnings Per Share (EPS) for the annual period ending March 2026 was Rs 10.43.
Balance Sheet
Anthem Biosciences Ltd. maintains a low debt-to-equity ratio of 0.08, indicating a relatively low reliance on debt financing. The book value per share is Rs 43.1.
Ownership & Pledges
As of June 30, 2026, promoters held 71.4165% of the company's shares. Public shareholding was 12.5295%, FIIs held 2.5764%, and DIIs held 13.4776%. There are no promoter shares pledged.
Regulatory & Surveillance
The company is not currently under any form of surveillance, indicating normal trading activity and regulatory compliance.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.